Joseph Joseph
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph Joseph has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kelvin Truong
Department of Dermatology Sydney Children's Hospital Randwick New South Wales Australia
6 shared publications Annika Smith
St Vincents Hosp, Darlinghurst, NSW, Australia
3 shared publications- Artiene Tatian
School of Clinical Medicine, University of New South Wales
2 shared publications - Orli Wargon
Department of Dermatology Sydney Children's Hospital Randwick New South Wales Australia
2 shared publications - Pablo Fernández-Peñas
Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
2 shared publications - Alexandra Murray
Department of Dermatology Westmead Hospital Westmead New South Wales Australia
1 shared publication
Latest Publications
- Open Access
- 26 July 2026
- Published by Wiley in Australasian Journal of Dermatology
A Systematic Review of Topical and Systemic Gentamicin for Wound Healing in Patients With Junctional and Dystrophic Epidermolysis Bullosa
Epidermolysis bullosa (EB) is an inherited mechanobullous genodermatosis caused by a mutation in genes encoding proteins integral to skin integrity. Premature termination codon readthrough therapies, such as gentamicin, have promise in facilitating full‐length protein expression in patients with EB. We conducted a systematic review of the effectiveness and adverse effects of gentamicin for wound healing in EB. Six databases were searched to 01 September 2025 for clinical trials investigating gentamicin for EB. Risk of bias was assessed using the ROBINS‐I tool, and data were synthesised descriptively. This study was registered with PROSPERO (CRD42024496582). Five studies involving 24 patients with junctional EB or dystrophic EB were included; four were open‐label and one was double‐blinded. Nineteen of the 24 patients had a known nonsense mutation. Gentamicin was administered topically (two studies), intravenously (two studies) and both topically and intradermally (one study). Wound healing was heterogeneously measured across studies, with all but one showing improved outcomes. All patients demonstrated increased expression of glycoprotein or collagen in skin biopsy specimens after gentamicin treatment. No adverse events were noted. However, four of five studies were at serious risk of bias on ROBINS‐I, primarily owing to lack of blinding and absence of control groups, increasing the risk of bias for subjective outcomes such as wound healing. The available evidence suggests gentamicin may improve wound healing in EB caused by nonsense mutations, but the small number of heterogeneous studies precludes high‐level evidence. Larger, blinded, randomised trials are required to confirm efficacy and long‐term safety.
- 26 July 2026
- Published by Wiley in Australasian Journal of Dermatology
Open AccessA Systematic Review of Topical and Systemic Gentamicin for Wound Healing in Patients With Junctional and Dystrophic Epidermolysis Bullosa
Epidermolysis bullosa (EB) is an inherited mechanobullous genodermatosis caused by a mutation in genes encoding proteins integral to skin integrity. Premature termination codon readthrough therapies, such as gentamicin, have promise in facilitating full‐length protein expression in patients with EB. We conducted a systematic review of the effectiveness and adverse effects of gentamicin for wound healing in EB. Six databases were searched to 01 September 2025 for clinical trials investigating gentamicin for EB. Risk of bias was assessed using the ROBINS‐I tool, and data were synthesised descriptively. This study was registered with PROSPERO (CRD42024496582). Five studies involving 24 patients with junctional EB or dystrophic EB were included; four were open‐label and one was double‐blinded. Nineteen of the 24 patients had a known nonsense mutation. Gentamicin was administered topically (two studies), intravenously (two studies) and both topically and intradermally (one study). Wound healing was heterogeneously measured across studies, with all but one showing improved outcomes. All patients demonstrated increased expression of glycoprotein or collagen in skin biopsy specimens after gentamicin treatment. No adverse events were noted. However, four of five studies were at serious risk of bias on ROBINS‐I, primarily owing to lack of blinding and absence of control groups, increasing the risk of bias for subjective outcomes such as wound healing. The available evidence suggests gentamicin may improve wound healing in EB caused by nonsense mutations, but the small number of heterogeneous studies precludes high‐level evidence. Larger, blinded, randomised trials are required to confirm efficacy and long‐term safety.
- 2 September 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7)
Safety and Efficacy of Angiotensin Receptor Antagonists in Recessive Dystrophic Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited progressive blistering skin disorder caused by mutations in the COL7A1 gene. Chronic wounds lead to cycles of scarring and healing, causing severe functional deformities. Losartan is an angiotensin II type 1 receptor (AT1R) antagonist that has been shown to have antifibrotic activity via inhibiting the production of transforming growth factor beta (TGF‐B) and has a favourable safety profile in children. In this systematic review, there were five studies found, with a total of 59 patients including case series, case–control and an open label phase 2 clinical trial. These studies have demonstrated the safety of losartan with no significant adverse effects such as hypotension, hyperkalaemia and hypersensitivity. They have also demonstrated evidence of efficacy utilising subjective assessments and objective criteria such as the Birmingham Epidermolysis Bullosa Severity score (BEBS) and Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Although safe and effective, further clinical trials are required to fully elucidate the role of this treatment; whether this approach should be standardised across the RDEB patient cohort is yet to be determined from the current evidence. Trial Registration: PROSPERO ID: CRD42024557126
- 2 September 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (7)
Safety and Efficacy of Angiotensin Receptor Antagonists in Recessive Dystrophic Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited progressive blistering skin disorder caused by mutations in the COL7A1 gene. Chronic wounds lead to cycles of scarring and healing, causing severe functional deformities. Losartan is an angiotensin II type 1 receptor (AT1R) antagonist that has been shown to have antifibrotic activity via inhibiting the production of transforming growth factor beta (TGF‐B) and has a favourable safety profile in children. In this systematic review, there were five studies found, with a total of 59 patients including case series, case–control and an open label phase 2 clinical trial. These studies have demonstrated the safety of losartan with no significant adverse effects such as hypotension, hyperkalaemia and hypersensitivity. They have also demonstrated evidence of efficacy utilising subjective assessments and objective criteria such as the Birmingham Epidermolysis Bullosa Severity score (BEBS) and Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Although safe and effective, further clinical trials are required to fully elucidate the role of this treatment; whether this approach should be standardised across the RDEB patient cohort is yet to be determined from the current evidence. Trial Registration: PROSPERO ID: CRD42024557126
- Open Access
- 23 September 2024
- Published by Wiley in Medical Journal of Australia
- Vol. 221 (8) , 434-435
An outbreak of reactive infectious mucocutaneous eruption (RIME) after Mycoplasma pneumoniae infections in Sydney, 2024: retrospective case series
Click on the article title to read more.
- 23 September 2024
- Published by Wiley in Medical Journal of Australia
- Vol. 221 (8) , 434-435
Open AccessAn outbreak of reactive infectious mucocutaneous eruption (RIME) after Mycoplasma pneumoniae infections in Sydney, 2024: retrospective case series
Click on the article title to read more.
- Open Access
- 11 May 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (5) , e249818
Dermoscopic changes to a melanocytic naevi from intense pulse light therapy
A male in his 40s with Fitzpatrick skin type III and multiple melanocytic naevi, known to the dermatology department for more than 2 years, presented for a skin examination. He had a personal history of two melanoma in situ and a family history of invasive melanoma. On sequential digital dermoscopy, two melanocytic naevi displayed several blotches of brown pigment within a reticular network, which was not evident previously (figure 1).
- 11 May 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (5) , e249818
Open AccessDermoscopic changes to a melanocytic naevi from intense pulse light therapy
A male in his 40s with Fitzpatrick skin type III and multiple melanocytic naevi, known to the dermatology department for more than 2 years, presented for a skin examination. He had a personal history of two melanoma in situ and a family history of invasive melanoma. On sequential digital dermoscopy, two melanocytic naevi displayed several blotches of brown pigment within a reticular network, which was not evident previously (figure 1).
- 29 March 2022
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (6) , 526-539
Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta‐analysis
Introduction: Epidermal growth factor receptor (EGFR) inhibitors are established therapies for advanced lung, colorectal, and head and neck cancers. They commonly cause acneiform eruptions that affect patient quality of life and may lead to discontinuation of therapy.Methods: A systematic review and meta‐analysis was undertaken to assess strategies for the prevention and reactive management of acneiform rash associated with EGFR inhibitor therapy for advanced lung, colorectal, and head and neck cancers. A systematic Medline, Embase, and EBM Reviews database search was conducted on the 2nd of January 2021. The Preferred Reporting Items for Systematic Reviews and Meta‐analyses statement was followed and the studies were critically appraised. Studies were selected if they focused on preventing or treating acneiform eruptions in adults being treated for advanced lung cancer, colorectal cancer, and head and neck cancers with EGFR inhibitors.Results: Oral antibiotics had the greatest efficacy in preventing grade 2 or higher acneiform eruptions with a relative risk reduction of 40% (RR = .6, 95% CI .46–.79, p < .01). Other treatment modalities did not have statistically significant results. Topical antibiotics had a total relative risk reduction of 19% (RR = .81, 95% CI .45–1.48, p = .5). Vitamin K1 cream did not reduce the relative risk (RR = 1.08, 95% CI .45–1.48, p = .50). Sunscreen had a total relative risk reduction of 25% (RR = .75, 95% CI .49–1.14, p = .18).Conclusions: The results of this meta‐analysis reinforce the fact that oral tetracycline antibiotics are the most efficacious prophylactic option for acneiform eruptions in EGFR inhibitors. They should be offered to suitable patients commencing treatment and used with a general skin‐care routine involving emollients and avoidance of irritants.
- 29 March 2022
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 18 (6) , 526-539
Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta‐analysis
Introduction: Epidermal growth factor receptor (EGFR) inhibitors are established therapies for advanced lung, colorectal, and head and neck cancers. They commonly cause acneiform eruptions that affect patient quality of life and may lead to discontinuation of therapy.Methods: A systematic review and meta‐analysis was undertaken to assess strategies for the prevention and reactive management of acneiform rash associated with EGFR inhibitor therapy for advanced lung, colorectal, and head and neck cancers. A systematic Medline, Embase, and EBM Reviews database search was conducted on the 2nd of January 2021. The Preferred Reporting Items for Systematic Reviews and Meta‐analyses statement was followed and the studies were critically appraised. Studies were selected if they focused on preventing or treating acneiform eruptions in adults being treated for advanced lung cancer, colorectal cancer, and head and neck cancers with EGFR inhibitors.Results: Oral antibiotics had the greatest efficacy in preventing grade 2 or higher acneiform eruptions with a relative risk reduction of 40% (RR = .6, 95% CI .46–.79, p < .01). Other treatment modalities did not have statistically significant results. Topical antibiotics had a total relative risk reduction of 19% (RR = .81, 95% CI .45–1.48, p = .5). Vitamin K1 cream did not reduce the relative risk (RR = 1.08, 95% CI .45–1.48, p = .50). Sunscreen had a total relative risk reduction of 25% (RR = .75, 95% CI .49–1.14, p = .18).Conclusions: The results of this meta‐analysis reinforce the fact that oral tetracycline antibiotics are the most efficacious prophylactic option for acneiform eruptions in EGFR inhibitors. They should be offered to suitable patients commencing treatment and used with a general skin‐care routine involving emollients and avoidance of irritants.
- 1 February 2022
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 51 (1-2) , 47-49
Targeting an acute skin eruption
A male aged 16 years presented to the emergency department with a three-day history of oral ulceration involving the lips that was associated with skin and genital lesions.
- 1 February 2022
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 51 (1-2) , 47-49
Targeting an acute skin eruption
A male aged 16 years presented to the emergency department with a three-day history of oral ulceration involving the lips that was associated with skin and genital lesions.
- 1 December 2021
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 50 (12) , 887-892
Infantile haemangiomas: Identifying high-risk lesions in primary care
General practitioners are ideally placed to identify high-risk infantile haemangiomas and coordinate their management.
- 1 December 2021
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 50 (12) , 887-892
Infantile haemangiomas: Identifying high-risk lesions in primary care
General practitioners are ideally placed to identify high-risk infantile haemangiomas and coordinate their management.
- 1 November 2021
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 50 (11) , 830-832
Dressing a wound with a sanitary pad: A case of contact dermatitis
A woman aged 42 years presented to the hospital with a one-week history of a wrist lesion.
- 1 November 2021
- Published by The Royal Australian College of General Practitioners in Australian Journal of General Practice
- Vol. 50 (11) , 830-832
Dressing a wound with a sanitary pad: A case of contact dermatitis
A woman aged 42 years presented to the hospital with a one-week history of a wrist lesion.
- 27 September 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (4) , E582-E585
Adherence to suggestions after dermatology consultation in a tertiary hospital – a retrospective analysis
Dermatology consultation is a valuable inpatient service in Australian hospitals. Adherence rates to consultative advice in international literature range between 67.4% and 93%. This study identifies that adherence rates to suggested investigations and management in a tertiary Australian hospital are at the lower end of the range reported in previous literature.
- 27 September 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (4) , E582-E585
Adherence to suggestions after dermatology consultation in a tertiary hospital – a retrospective analysis
Dermatology consultation is a valuable inpatient service in Australian hospitals. Adherence rates to consultative advice in international literature range between 67.4% and 93%. This study identifies that adherence rates to suggested investigations and management in a tertiary Australian hospital are at the lower end of the range reported in previous literature.
- 9 July 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (1) , 48-53
Dermatology inpatient consultations in a tertiary hospital – a retrospective analysis
Background: Dermatology consultation has been shown to have a significant beneficial impact on admitted hospital patients with concurrent or newly diagnosed skin conditions. This study aimed to determine the change in diagnosis and management after dermatology consultation in a tertiary Australian referral hospital.Methods: A retrospective analysis of dermatology consultations for hospital inpatients from June 1, 2018, through November 11, 2019, was performed. Demographic and clinical data were extracted from electronic medical records, and a chi‐squared test was used to analyze categorical variables.Results: There were 306 consultations during the period of interest. The male to female ratio was 1:1 with a median age of 63. Consultations were most often requested by medical teams (69%), and the majority of patients seen in the emergency department were discharged home (86%). In 44% of cases, the requesting team did not provide a diagnosis; in the cases where it did provide a diagnosis, it was changed 57.9% of the time. The most commonly misdiagnosed conditions were dermatitis and skin infections. Dermatologists established or changed management in 82% of cases, and a total of 676 suggestions were made for management.Conclusion: The results of this review reinforce the value of dermatology input in the diagnosis and management of hospital in patients. Ensuring maintained presence of hospital‐based dermatologists has the potential to improve diagnosis and management of cutaneous issues early on; by extension, this can minimize unnecessary investigations, improve the quality of healthcare, reduce hospital burden, and facilitate outpatient follow‐up.
- 9 July 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (1) , 48-53
Dermatology inpatient consultations in a tertiary hospital – a retrospective analysis
Background: Dermatology consultation has been shown to have a significant beneficial impact on admitted hospital patients with concurrent or newly diagnosed skin conditions. This study aimed to determine the change in diagnosis and management after dermatology consultation in a tertiary Australian referral hospital.Methods: A retrospective analysis of dermatology consultations for hospital inpatients from June 1, 2018, through November 11, 2019, was performed. Demographic and clinical data were extracted from electronic medical records, and a chi‐squared test was used to analyze categorical variables.Results: There were 306 consultations during the period of interest. The male to female ratio was 1:1 with a median age of 63. Consultations were most often requested by medical teams (69%), and the majority of patients seen in the emergency department were discharged home (86%). In 44% of cases, the requesting team did not provide a diagnosis; in the cases where it did provide a diagnosis, it was changed 57.9% of the time. The most commonly misdiagnosed conditions were dermatitis and skin infections. Dermatologists established or changed management in 82% of cases, and a total of 676 suggestions were made for management.Conclusion: The results of this review reinforce the value of dermatology input in the diagnosis and management of hospital in patients. Ensuring maintained presence of hospital‐based dermatologists has the potential to improve diagnosis and management of cutaneous issues early on; by extension, this can minimize unnecessary investigations, improve the quality of healthcare, reduce hospital burden, and facilitate outpatient follow‐up.